The FDA removed BPC-157 from the list of substances that can be used by compounding pharmacies specifically, its no longer on the 503A or 503B bulk drug substance lists that allow compounders to make non-FDA-approved drugs legally
This treatment paradigm reduces post-prandial TRL-fraction TG levels and ApoB48 production (Hsieh et al., 2010)
Endocrinology 152 (12), 46304640 (2011)
Goals Improve body composition Boost metabolic function Support consistent, sustainable weight loss Increase energy and motivation Treatmentable Areas Busy professionals, post-baby glow-getters, and anyone ready to ditch yo-yo dieting in favor of real, lasting change
While Nestl made waves with the release of Vital Pursuit, a brand that explicitly controls portions and increases proteins with GLP-1 users in mind, other companies are taking a more tempered approach
Compounded semaglutide and tirzepatide are well-established GLP-1 receptor agonists with substantial clinical evidence supporting weight loss
